EE81 Cost-Effectiveness of CDK 4/6I for the Treatment of Postmenopausal Patients With Advanced Breast Cancer HR-Positive, HER2-Negative From the Point of View of the Payer of the Public Health System in Panama

The aim of this study is to estimate the cost-effectiveness of ribociclib + letrozole, Abemaciclib + letrozole or ANAS (Anastrozole) versus palbociclib + letrozole in the treatment of HR-positive, HER2-negative advanced breast cancer patients in the first line of treatment from the perspective of the National Cancer Institute of Panama (ION).
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research